Herpes virus strains
AssigneeAmgen Inc.
InventorRobert S. COFFIN
Life of this patent
Estimating the term…
Abstract
The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.
Claims43
A herpes virus which comprises a gene encoding an immunomodulatory protein, which lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene and which is replication competent in tumour cells.
An agent for treating cancer comprising a herpes virus which comprises a gene encoding an immunomodulatory cytokine, which lacks a functional ICP34.5-encoding gene and a functional ICP47 encoding gene and which is replication competent in tumour cells.
HSV1 strain JSI as deposited as the European Collection of Cell. Cultures (ECACC) under provisional accession number 01010209, or an HSV1 strain derived therefrom.
A method of treating cancer in an individual in need thereof by administering to a tumor in said individual a therapeutically effective amount of a herpes simplex virus which:
- (i) comprises an immunostimulatory protein;
- (ii) lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene;
- and (iii) is replication competent in infected tumor cells.
A herpes simplex virus which:
- (i) comprises a gene encoding an immunostimulatory protein selected from GM-CSF and a chemokine;
- (ii) lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene;
- and (iii) is replication competent in infected tumor cells.
Dependencies are inferred from the claim text.